Eterna Therapeutics Inc. (ERNA) Year-over-year earnings per share growth for the last twelve months

Eterna Therapeutics, Inc. - graphic logo of issuer ERNA

Despite strict control over reagent supply chains, Eterna Therapeutics (ERNA) dominates cell engineering through mRNA synthesis and precise genome editing. Changes in quarterly EPS dynamics on GURU.Markets reflect the current trend, where the current level equals 50.40. Success is driven by elite biologists attracted by stable R&D funding and high social guarantees for the fight against oncology.

eternatx.com (ERNA) - Year-over-year earnings per share growth for the last 12 months from 04/28/2023 to 11/16/2026

eternatx.com - analytical breakdowns and key metrics (ERNA)

- market value and analyst target forecast:
Comprehensive company analysis:Eterna Therapeutics
Finished products of Eterna Therapeutics

Analyzing the quarterly percentage growth in earnings per share allows for an assessment of the effectiveness of the Eterna Therapeutics (ERNA) strategy to implement mRNA technologies in oncology. This metric captures the dynamics of net income per share relative to the previous period, enabling investors to differentiate fundamental growth from short-term speculative impulses and identify the asset's correction phase in a timely manner.

Who Eterna Therapeutics competes with

tgtherapeutics.com (TGTX) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Arcellx Therapeutics (ACLX)|Year-over-year earnings per share growth for the last twelve months Disc Medicine Inc|Earnings per share growth in annualized terms for the last twelve months Syndax Pharmaceuticals SNDX|Quarterly EPS earnings growth KURA|ADC Therapeutics SA - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth FHTX (Foghorn Therapeutics, Inc.)|Vor Bio Inc. (VOR) - Earnings per share growth in annualized terms for the last twelve months|NKTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months coeptistx.com|ATNM (Actinium Pharmaceuticals) - Year-over-year net earnings per share growth for the last 12 months|ESLA: Year-over-year earnings per share growth rate for the last twelve months|CASI (CASI Pharmaceuticals, Inc.) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Marker Therapeutics|INAB (IN8bio, Inc.) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share change for the last twelve months gtbiopharma.com|Quarterly EPS earnings growth APTO (Aptose Biosciences)|Quarterly EPS earnings growth Bio-Path BPTH|MEI Pharma Inc - Quarterly EPS earnings growth|VINC (Vincerx Pharma Inc.) - Year-over-year earnings per share growth for the last 12 months